In summary, our study firstly reveals a novel and critical role of miR-27a in regulating hepatic DNL and NAFLD development via targeting Fasn and Scd1. These findings provide new insights for understanding obesity-associated NAFLD progression and also novel promising therapeutic target for NAFLD. This evidence concerns the gene SCD and metabolic dysfunction-associated steatotic liver disease.